



Thank you for selecting our infusion services team to care for your patient. If you are not a PeaceHealth provider, all information listed below is required before we can process orders and schedule your patient for treatment.

Part A- Patient scheduling and contact information:

Patient Name (Last, First): _____ Date of Birth: _____

Patient Contact Information and Phone Number (s): _____

Ordering Provider Name (Print): _____

Provider Clinic or Service Address: _____

Clinic or Service Phone Number: _____ Clinic or Service Fax Number: _____

Diagnosis (include ICD 10 codes): _____

Medication and Service Requested- list J-Code/ CPT code if known: _____

Date Service is Requested to Begin: _____ **Date Service is Expected to End:** _____

Order will expire 1 year from date of provider signature unless "date service is expected to end" is earlier.

Part B- Insurance and Prior Authorization. Any non-PeaceHealth provider must obtain prior authorization prior to service. Attach a copy of authorization documentation received from insurance payer when submitting orders.

Insurance (Payer) Company: _____

Prior Authorization Number and Conditions: _____

Prior Authorization Expiration Date: _____

Insurance (Payer) Contact Phone Number: _____

Part C- Elements needed to guide medication therapy are included with request for service:

- All orders and instruction (please use the PeaceHealth approved ordering form) are complete and include provider signature AND printed name at the bottom of each order page. Check the boxes of ALL orders you would like to activate.
- For blood products, PeaceHealth Blood and Transfusion Consent form is signed and dated by the provider and the patient.

If information is located outside of PeaceHealth's electronic medical record system attach the following:

- A list of current medications reconciled by patient provider is available and includes a list of known allergies.
- Recent progress notes from ordering provider.
- A copy of relevant laboratory results and other appropriate supporting documentation.

IMPORTANT MESSAGE TO PROVIDERS: To reduce delays in treatment and phone calls to your office you may participate in the PHMC formulary process by signing this document. A clinical pharmacist will adjust orders according to PHMC approved policies and procedures.

I agree to utilize PHMC policies & procedures that have been reviewed by the Pharmacy & Therapeutics Committee and authorized by the Medical Executive Committee of PHMC. This agreement will be issued for the duration of active orders contained within this treatment plan.

PROVIDER SIGNATURE: _____ **DATE:** _____ **TIME:** _____

FAX completed service request and completed orders to: PHMC OP Infusion and Nursing Services 541-902-1649



Ocrelizumab (Ocrevus) Outpatient Infusion Therapy Plan

All Pre-Selected Boxed Orders Are Initiated by Default Unless Crossed Out by Practitioner. All Boxed Orders Require Practitioner Check to be Initiated.

Heading	Content
For Admission to Service	<p>Provider Instruction – Please review information below and address requirements for admission to service:</p> <ol style="list-style-type: none"> 1. Provider has screened patient for active hepatitis B virus infection, latent hepatitis and tuberculosis infections in high-risk populations, malignancy, and history of chronic infections prior to initiation of Ocrevus. Ocrevus is contraindicated in patients with an active hepatitis B infection. Hepatitis B screening is required before first dose. Please order and evaluate required hepatitis B screening labs (hepatitis B surface antigen HBsAg and hepatitis B core antibody HBCAb) outside of this therapy plan prior to ordering Ocrevus. <p>Date of screening (required for service): _____</p> <ol style="list-style-type: none"> 2. Provider has verified that patient is up to date with all immunizations prior to initiation of Ocrevus. Live vaccines must be given at least 4 weeks prior to initiation of Ocrevus, and non-live vaccines must be given at least 2 weeks prior to initiation of Ocrevus. 3. Instruct patients that if they are pregnant or plan to become pregnant while taking Ocrevus, they should inform their healthcare provider. 4. Review the FDA approved medication guide for ocrelizumab (Ocrevus) with the patient and provide patient with a paper copy.
Labs	<input type="checkbox"/> CBC with automated differential once prior to beginning treatment and every _____ months <input type="checkbox"/> Comprehensive metabolic panel once prior to beginning treatment and every _____ months <input type="checkbox"/> Other: _____
Pre-Medications	<input checked="" type="checkbox"/> MethylPREDNISolone sodium succinate (Solu-MEDROL) 125 mg IV once 30 minutes prior to infusion <input checked="" type="checkbox"/> Acetaminophen (Tylenol) 650 mg PO once 30 minutes prior to infusion <input checked="" type="checkbox"/> DiphenhydrAMINE (Benadryl) 25 mg PO once 30 minutes prior to infusion
Supportive Care	<input checked="" type="checkbox"/> Ocrelizumab (Ocrevus) IV infusion Select Regimen: <input type="checkbox"/> Initiation: 300 mg at zero (0) and 2 weeks followed by 600 mg maintenance infusion every 6 months <input type="checkbox"/> Maintenance: 600 mg every 6 months Additional order instruction: <input checked="" type="checkbox"/> Administer through a dedicated IV line using a 0.2 or 0.22 micron in-line filter. For 300 mg doses begin infusion at 30 ml/hour and increase by 30 ml/hour every 30 minutes to a maximum rate of 180 ml/hour. For 600 mg doses begin infusion at 40 ml/hour and increase by 40 ml/hour every 30 minutes to a maximum rate of 200 ml/hour.
Nursing Orders	<input checked="" type="checkbox"/> Ocrevus is contraindicated in patients with an active hepatitis B infection. On initial visit, verify that hepatitis B screening is complete. <input checked="" type="checkbox"/> Vital signs to be done at baseline, as needed during and after infusion, and prior to discharge. <input checked="" type="checkbox"/> Observe patients for infusion reactions during and for at least one hour after completion of infusion. For mild to moderate infusion reactions reduce infusion to one-half of the rate at which the reaction occurred and maintain reduced rate for at least 30 minutes. If the reduced rate is tolerated, increase rate every 30 minutes by 30 ml/hour to a maximum rate of 180 ml/hour (300 mg dose) or 40 ml/hour to a maximum rate of 200 ml/hour (600 mg dose). For severe infusion reactions immediately interrupt infusion and notify provider. Administer appropriate supportive management as needed. After symptoms have resolved, restart infusion beginning at a rate one-half of the rate at the onset of reaction. If reduced rate is tolerated, increase the rate as above. For

Practitioner Signature: _____ **Date of Order:** _____ **Time:** _____

Final page of orders must include signature of the ordering practitioner, date, and time.



Ocrelizumab (Ocrevus) Outpatient Infusion Therapy Plan

All Pre-Selected Boxed Orders Are Initiated by Default Unless Crossed Out by Practitioner. All Boxed Orders Require Practitioner Check to be Initiated.

Heading	Content
	life threatening infusion reaction immediately stop infusion, notify provider, and administer appropriate supportive care. Permanently discontinue.
Nursing IV Access and Maintenance	<p>Select the most appropriate option below:</p> <p><input checked="" type="checkbox"/> Insert PERIPHERAL IV as needed and flush (unless provider selects option for a central line).</p> <p><input checked="" type="checkbox"/> Sodium chloride 0.9% (NS) flush 10 mL IV once as needed for line care.</p> <p><input type="checkbox"/> Access and use NON-PICC Central Line/CVAD</p> <p><input checked="" type="checkbox"/> Initiate Central Line (non-PICC) maintenance protocol.</p> <p><input checked="" type="checkbox"/> Sodium chloride 0.9% (NS) flush 10 mL IV as needed for line care, before and after medication administration, at discharge, and at de-access (sterile NS for Port-a-Cath access)</p> <p><input checked="" type="checkbox"/> Sodium chloride 0.9% (NS) flush 20 mL IV as needed for line care post lab draw.</p> <p><input checked="" type="checkbox"/> Heparin, porcine (PF) 100 unit/mL flush 5 mL IV as needed for line care, for de-access.</p> <p><input type="checkbox"/> Alteplase (Cathflo) injection 2 mg intra-catheter as needed for occluded central line catheters- For clearing central line catheter. Add 2.2 mL sterile water for injection to vial; let the vial stand undisturbed to allow large bubbles to dissipate. Mix by gently swirling until completely dissolved (complete dissolution should occur within 3 minutes); do not shake. Final concentration: 1mg/mL. Retain in catheter for 30 minutes to 2 hours; may instill a second dose if occluded.</p> <p><input type="checkbox"/> Access and use PICC Central Line/CVAD</p> <p><input checked="" type="checkbox"/> Initiate PICC maintenance protocol.</p> <p><input checked="" type="checkbox"/> Change PICC line dressing weekly and as needed.</p> <p><input checked="" type="checkbox"/> Sodium chloride 0.9% (NS) flush 10 mL IV as needed for line care, and before and after medication administration.</p> <p><input checked="" type="checkbox"/> Sodium chloride 0.9% (NS) flush 20 mL IV as needed for line care post lab draw</p> <p><input type="checkbox"/> Alteplase (Cathflo) injection 2 mg intra-catheter as needed for occluded central line catheters- For clearing central line catheter. Add 2.2 mL sterile water for injection to vial; let the vial stand undisturbed to allow large bubbles to dissipate. Mix by gently swirling until completely dissolved (complete dissolution should occur within 3 minutes); do not shake. Final concentration: 1mg/mL. Retain in catheter for 30 minutes to 2 hours; may instill a second dose if occluded.</p>
As Needed Medications	<p>Standard As Needed Medications:</p> <p><input checked="" type="checkbox"/> Sodium chloride 0.9% (NS) flush 10 mL IV as needed for line care</p> <p><input checked="" type="checkbox"/> Sodium chloride 0.9% 500 mL continuous infusion at 25 mL/hour IV as needed for therapy administration (i.e., blood products, chemotherapy, potassium administration).</p>
Emergency Medications	<p>If patient has symptoms of anaphylaxis (wheezing, dyspnea, hypotension, angioedema, chest pain, or tongue swelling), discontinue infusion and initiate standard emergency response procedures.</p> <p>Standard Emergency Medications:</p> <p><input checked="" type="checkbox"/> DiphenhydrAMINE (Benadryl) injection 25-50 mg IV once as needed for mild to moderate drug reactions (flushing, dizziness, headache, diaphoresis, fever, palpitations, chest discomfort, blood pressure changes (>= 20 points in SBP), nausea, urticaria, chills, pruritis).</p> <ul style="list-style-type: none"> Administer 50 mg IV if patient has NOT had diphenhydramine within 2 hours of reaction

Practitioner Signature: _____ Date of Order: _____ Time: _____

Final page of orders must include signature of the ordering practitioner, date, and time.

Patient Identification Label



**Ocrelizumab (Ocrevus)
Outpatient Infusion Therapy Plan**

All Pre-Selected Boxed Orders Are Initiated by Default Unless Crossed Out by Practitioner. All Boxed Orders Require Practitioner Check to be Initiated.

Heading	Content
	<ul style="list-style-type: none"> • Administer 25 mg IV if patient has had diphenhydramine within 2 hours of reaction, if reaction doesn't resolve in 3 minutes may repeat 25 mg IV dose for a total of 50 mg and contact provider. <input checked="" type="checkbox"/> Albuterol 90 mcg/actuation inhaler 2 puffs once as needed for wheezing, shortness of breath associated with infusion reaction and contact provider. Administer with spacer if available. <input checked="" type="checkbox"/> MethylPREDNISolone (Solu-Medrol) injection 125 mg IV once as needed for shortness of breath for continued symptoms of mild to moderate drug reactions (flushing, dizziness, headache, diaphoresis, fever, palpitations, chest discomfort, blood pressure changes (>/= 20 points in SBP), nausea, urticaria, chills, pruritis) that worsen or persist 5 minutes after administration of diphenhydramine (Benadryl) and contact provider. <input checked="" type="checkbox"/> EPINEPHrine (Adrenalin) injection 0.5 mg IM once as needed for severe drug reaction (flushing, dizziness, headache, diaphoresis, fever, palpitations, chest discomfort plus blood pressure changes (>/= 40 points in SBP), shortness of breath with wheezing and O2 Sat < 90%) and contact provider.
Referral	<input checked="" type="checkbox"/> Ambulatory referral to OP Infusion Services
PHMC Outpatient Infusion Contact Information	<p>PROVIDER – PLEASE SIGN, DATE AND TIME ORDERS AND RETURN TO:</p> <p>PeaceHealth Peace Harbor Medical Center Outpatient Infusion Services Department 400 Ninth Street Florence, OR 97439 Contact Phone: 541-902-6019 and FAX 541-902-1649</p>
Authorization by Verbal or Telephone Order	Person giving verbal or telephone order: _____ Person receiving verbal or telephone order: _____ <input type="checkbox"/> Check to indicate verbal or telephone orders have been read back to confirm accuracy

Practitioner Signature: _____ **Date of Order:** _____ **Time:** _____

Final page of orders must include signature of the ordering practitioner, date, and time.